Shanghai Junshi Biosciences Co., Ltd. (SHJBF)

Market Cap	5.36B +54.7%
Revenue (ttm)	394.95M +31.7%
Net Income	-95.81M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	899
Open	3.350
Previous Close	n/a
Day's Range	3.350 - 3.350
52-Week Range	2.990 - 4.229
Beta	0.61
RSI	29.22
Earnings Date	Apr 27, 2026

About SHJBF

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2,903
• Stock Exchange: OTCMKTS
• Ticker Symbol: SHJBF

Financial Performance

In 2025, SHJBF's revenue was 2.50 billion, an increase of 28.23% compared to the previous year's 1.95 billion. Losses were -875.17 million, -31.68% less than in 2024.

Financial numbers in CNY